Bevacizumab and recurrent malignant gliomas: A European perspective

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages

  Wick, Wolfgang ^a   Weller, Michael ^b   Van Den Bent, Martin ^c   Stupp, Roger ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; IRINOTECAN; OXALIPLATIN; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER RADIOTHERAPY; COLORECTAL CANCER; DRUG INDICATION; EUROPE; GLIOBLASTOMA; HUMAN; LETTER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SURVIVAL; BRAIN TUMOR; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; METHODOLOGY; NOTE; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; EUROPE; EVIDENCE-BASED MEDICINE; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77951648711     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.9027     Document Type: Letter

References (14)

1. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
2. van den Bent MJ, Vogelbaum MA, Wen PY, et al: End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 27:2905-2908, 2009
3. Chen W, Delaloye S, Silverman DH, et al: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25:4714-4721, 2007 (Pubitemid 350086472)
4. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
5. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
6. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
7. Center for Drug Evaluation and Research: Summary Minutes of the Oncologic Drugs Advisory Committee March 31, 2009. Washington, DC, US Food and Drug Administration, 2009 http://www.fda.gov/ohrms/dockets/ac/09/minutes/2009-4427m1- final.pdf
8. Macdonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
9. Lamborn KR, Yung WK, Chang SJ, et al: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol 10:162-170, 2008
10. Wick W, Puduvalli VK, Chamberlain MC, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-1174, 2010
11. Kamoun WS, Ley CD, Farrar CT, et al: Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542-2552, 2009
12. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol 7:369, 2005 (suppl; abstr 342)
13. Tol J, Koopman M, Rodenburg CJ, et al: A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG): An interim analysis of toxicity. Ann Oncol 19:734-738, 2008 (Pubitemid 351461045)
14. Norden AD, Drappatz J, Muzikansky A, et al: An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149-155, 2009